Arrowhead Research reported $16.87M in Interest Income for its fiscal quarter ending in March of 2026.





Interest Income Change Date
Agios Pharmaceuticals USD 10.8M 1.62M Mar/2026
Alnylam Pharmaceuticals USD 26.6M 32K Mar/2026
Arrowhead Research USD 16.87M 7.18M Mar/2026
Heron Therapeutics USD 433K 277K Dec/2021
Incyte USD 38.12M 4.43M Jun/2026
Ionis Pharmaceuticals USD -0.66 0.29 Dec/2024
Ligand Pharmaceuticals USD 6.65M 262K Mar/2026
Merck USD 35M 34M Mar/2026
Moderna USD 72M 2M Mar/2026
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Sarepta Therapeutics USD 7M 1.74M Mar/2026
Ultragenyx Pharmaceutical USD 6M 512K Mar/2026
Vertex Pharmaceuticals USD 114.8M 7.1M Mar/2026
Xencor USD 5.46M 741K Mar/2026